Posted by Michael Wonder on 08 Apr 2022
NICE recommends Koselugo for the treatment of neurofibromatosis type 1
8 April 2022 - NICE has recommended AstraZeneca and MSD’s Koselugo (selumetinib) for use by the NHS in England, within its marketing authorisation.
This treatment is indicated for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged three and over.
